Eli Lilly and Company $LLY Shares Purchased by SevenBridge Financial Group LLC

by · The Cerbat Gem

SevenBridge Financial Group LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 18.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,192 shares of the company’s stock after purchasing an additional 1,116 shares during the quarter. Eli Lilly and Company makes up 1.0% of SevenBridge Financial Group LLC’s holdings, making the stock its 21st largest position. SevenBridge Financial Group LLC’s holdings in Eli Lilly and Company were worth $5,606,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Braun Bostich & Associates Inc. boosted its stake in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after acquiring an additional 13 shares during the last quarter. Rise Advisors LLC lifted its holdings in Eli Lilly and Company by 1.8% in the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares in the last quarter. Occidental Asset Management LLC boosted its stake in Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors boosted its stake in Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after purchasing an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. grew its holdings in shares of Eli Lilly and Company by 2.8% during the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after buying an additional 13 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on LLY shares. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research note on Monday, November 10th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. HSBC restated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a report on Wednesday. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 8th. Finally, National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research report on Monday, December 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,121.90.

Get Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Trading Up 1.8%

NYSE LLY opened at $1,027.68 on Monday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The stock has a market capitalization of $971.55 billion, a P/E ratio of 50.28, a PEG ratio of 1.14 and a beta of 0.37. The firm’s 50-day moving average is $939.47 and its two-hundred day moving average is $820.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the business posted $1.18 EPS. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles